1 of 1
Story summary
- The World Health Organization reports that fewer than 10% of people who could benefit from obesity medications such as Wegovy have access.
- With over one billion people globally classified as obese, the WHO urges broader and fairer access to GLP-1 medications.
- Projections indicate the number could exceed two billion by 2030 without intervention.
- Major obstacles to universal access include high costs, limited production capacity, and supply-chain issues.
